Compare Nokia Corp (NOK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Recursion Pharmaceuticals Inc — how do they compare? Nokia Corp trades at $10.28 (market cap $56.99B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Nokia Corp is far larger — about 26.6× Recursion Pharmaceuticals Inc's market cap, and Nokia Corp pays a 1.61% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NOK | RXRX | |
|---|---|---|
Market Cap | $56.99B | $2.14B |
Volume | 69,968,204 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $16.83 | $6.79 |
52-Week Low | $5.18 | $2.84 |
Typical Hold Time | 66 Days | 22 Days |
Enterprise Value | $55.01B | $1.66B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.62, down 3.19% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights a strategic partnership with Microsoft for AI-driven network automation and sovereign satellite network development with ICEYE, positioning Nokia in high-growth infrastructure segments.
The outlook is supported by strong analyst sentiment with a consensus price target of $17.50, implying significant upside. Key opportunities include expanding AI and cloud orders, while risks involve competitive pressures and execution challenges in integrating new technologies. Cash flow volatility and a high P/E ratio of 78.9 warrant caution, but institutional buy ratings suggest confidence in long-term growth.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
